Ceryvyn Therapeutics Ltd. - Unsponsored ADR CYVNY
0.02
0.00
0.00%
as of 24 Sep
- Market cap
- $524.8M
- P/E
- 0.0×
Follow CYVNY
| Older periods | Dec '23 | Jun '24 | Dec '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
5.00 | 2.88 | 1.52 | 0.22 | |
Current Ratio |
5.10 | 2.94 | 1.57 | 0.22 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
108.60% | 106.22% | 152.78% | 0.00% | |
Debt/Equity |
(3.85) | (2.65) | (1.32) | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(69.36) | (161.05) | (72.58) | (158.66) | |
Working Capital |
133.75 | 124.14 | 52.38 | (201.07) | |
Capital Expenditures |
0.00 | (0.03) | (0.01) | (0.01) | |
Net Current Asset Value |
(47.08) | (76.41) | (170.35) | (201.07) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.60 | 9.19 | 8.57 | 7.08 | |
Average Payables |
20.01 | 24.78 | 19.35 | 13.81 | |
Average Assets |
137.86 | 124.42 | 149.89 | 77.72 | |
Average Common Equity |
26.68 | (13.92) | (56.12) | (103.46) |
Columns are period end dates